Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.41 |
| ▸ | METAP1 | P53582 | 3/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650369 | 1.00 | METAP2 (0.41) | METAP2METAP1PLA2G4AADAM17LMNA | |
| SCHEMBL6651146 | 1.00 | METAP2 (0.41) | METAP2METAP1PLA2G4AADAM17LMNA | |
| SCHEMBL31341209 | 0.86 | CTSA (0.38) | ADAM17SMN1; SMN2L3MBTL1CTSAHPGD | |
| SCHEMBL7269813 | 0.85 | HSPA1A (0.40) | ADAM17LMNACTSAPDPK1ALOX5 | |
| SCHEMBL7269821 | 0.85 | HSPA1A (0.40) | ADAM17LMNACTSAPDPK1ALOX5 | |
| SCHEMBL19258127 | 0.85 | HSPA1A (0.40) | ADAM17LMNACTSAPDPK1ALOX5 | |
| SCHEMBL7269817 | 0.85 | HSPA1A (0.40) | ADAM17LMNACTSAPDPK1ALOX5 | |
| SCHEMBL7269324 | 0.85 | HSPA1A (0.40) | ADAM17LMNACTSAPDPK1ALOX5 | |
| SCHEMBL7269816 | 0.85 | HSPA1A (0.40) | ADAM17LMNACTSAPDPK1ALOX5 | |
| Hydrochloric Acid SCHEMBL31341237 | 0.85 | CTSA (0.37) | ADAM17SMN1; SMN2L3MBTL1CTSAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | METAP2 863/4885METAP1 625/4885PLA2G4A 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.